1. Home
  2. DLTR vs INSM Comparison

DLTR vs INSM Comparison

Compare DLTR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dollar Tree Inc.

DLTR

Dollar Tree Inc.

HOLD

Current Price

$128.65

Market Cap

24.4B

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$127.14

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLTR
INSM
Founded
1986
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.4B
22.4B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
DLTR
INSM
Price
$128.65
$127.14
Analyst Decision
Hold
Strong Buy
Analyst Count
18
24
Target Price
$123.35
$201.17
AVG Volume (30 Days)
2.0M
3.1M
Earning Date
06-03-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
144.33
N/A
EPS
1.76
N/A
Revenue
$19,411,800,000.00
N/A
Revenue This Year
$8.48
$182.31
Revenue Next Year
$5.90
$65.19
P/E Ratio
$73.52
N/A
Revenue Growth
10.43
N/A
52 Week Low
$84.71
$90.39
52 Week High
$142.40
$212.75

Technical Indicators

Market Signals
Indicator
DLTR
INSM
Relative Strength Index (RSI) 56.49 62.28
Support Level $117.29 $95.24
Resistance Level $132.64 $140.30
Average True Range (ATR) 3.05 4.89
MACD -0.39 1.80
Stochastic Oscillator 48.02 74.10

Price Performance

Historical Comparison
DLTR
INSM

About DLTR Dollar Tree Inc.

Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: